Update on research and development pipeline: tuberculosis vaccines.
Current tuberculosis (TB)-control methods, which do not include an adequate vaccine, do not effectively block transmission of TB. Modeling studies show that mass vaccination campaigns using new vaccines could prevent 85.9 million new cases and 14.5 million deaths from 2015 through 2050 in southern Asia alone. After a dearth of many years, the development pipeline now includes 7 vaccine candidates that are being tested in humans. Two nonreplicating viral vectored vaccines have very recently entered the first phase IIb efficacy trial in infants (the first such trial in 80 years) and in human immunodeficiency virus-infected adults. Science is moving forward, but the scientific advancements need to be accompanied by political mobilization to ensure that the resources are available to develop, manufacture, and distribute the new vaccines and, thus, save millions of lives.
Beresford
Belinda
B
Aeras Global TB Vaccine Foundation, Rockville, Maryland 20850, USA. bberesford@aeras.org
Sadoff
Jerald C
JC
D035843:Biomedical Research / Q000639:trends*; D018562:Disease Transmission, Infectious / Q000517:prevention & control; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D014376:Tuberculosis / Q000453:epidemiology* / Q000276:immunology / Q000517:prevention & control*; D032581:Tuberculosis Vaccines / Q000276:immunology*
D032581:Tuberculosis Vaccines